Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • France
    • +34 96 390 53 10 Request Information
    • +34 96 390 53 10 Request Information
    FranceFrance
    • France
      • Part of brands: |
        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires

        Genomics Precision Diagnostic > Rare Disease Precision Panel > Noonan Spectrum Disorders and RASopathies Precision Panel

        Noonan Spectrum Disorders and RASopathies Precision Panel

        Noonan Syndrome is a genetic disorder that impairs normal development of several parts of the body. The main features of Noonan Syndrome include unusual fascies (hypertelorism, down-slanting eyes, webbed neck), congenital heart disease, short stature and chest deformity. 
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Noonan Syndrome is a genetic disorder that impairs normal development of several parts of the body. The main features of Noonan Syndrome include unusual fascies (hypertelorism, down-slanting eyes, webbed neck), congenital heart disease, short stature and chest deformity. Mental retardation can be seen in approximately 25% of individuals affected by Noonan syndrome. Other findings present to varying degrees include skeletal, neurologic, genitourinary, lymphatic, eye and skin manifestations. Gene mutations identified in individuals with Noonan Syndrome phenotype are involved in the RAS/MAPK (mitogen-activated protein kinase) signal transduction pathway, also known as RASopathy. RASopathies are developmental syndromes caused by germline mutations in genes that alter the RAS subfamily and MAPK that control signal transduction and that present overlapping clinical features. Some of the diseases belonging to this category include Noonan syndrome, Costello syndrome, Neurofibromatosis type 1, cardio–facio–cutaneous syndrome and others. The most common mode of inheritance for these diseases is autosomal dominant.  

        • The Igenomix Noonan Spectrum Disorders and RASopathies Precision Panel can be used to make a directed and accurate differential diagnosis of Noonan syndrome and RASopathies ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved

        Indication

        • The Igenomix Noonan Spectrum Disorders and RASopathies Precision Panel is indicated for those patients with a clinical diagnosis presenting with the following manifestations: 
          • Facial features: triangular-shaped face, hypertelorism, down-slanting palpebral fissures, ptosis, low set ears etc 
          • Ocular abnormalities: amblyopia, myopia, astigmatism, strabismus etc
          • Sensorineural hearing loss 
          • Pectus carinatum or excavatum 
          • Cardiac abnormalities: pulmonary stenosis, hypertrophic cardiomyopathy 
          • Skeletal features: joint laxity, short stature etc 
          • Skin abnormalities 
          • Genitourinary abnormalities  

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of treatment with a multidisciplinary team to perform appropriate medical care, early surveillance of malignancy and surgical repair of anatomic abnormalities. 
        • Risk assessment of asymptomatic family members according to the mode of inheritance.
        • Improvement of delineation of genotype-phenotype correlation.  

        Genes & Diseases

        See all genes and diseases

        GENE 

        OMIM DISEASES 

        INHERITANCE* 

        % GENE COVERAGE (20X) 

        HGMD** 

        A2ML1 

        Noonan Syndrome 

        AD,MU,P 

        100 

        23 of 23 

        ACTB 

        Baraitser-Winter Syndrome,
        Developmental Malformations-
        Deafness-Dystonia Syndrome
         

        AD 

        100 

        40 of 40 

        ACTG1 

        Baraitser-Winter 
        Syndrome
          

        AD 

        98.59 

        55 of 55 

        BRAF 

        Cardiofaciocutaneous Syndrome,
        Leopard Syndrome,
        Noonan Syndrome, 
        Cardiofaciocutaneous Syndrome
         

        AD 

        100 

        80 of 80 

        CBL 

        Noonan Syndrome-like
        Disorder With Or Without
        Juvenile Myelomonocytic
         Leukemia
         

        AD 

        100 

        46 of 47 

        CCNK 

        Intellectual Developmental
        Disorder With Hypertelorism
        And Distinctive Facies
         

        AD 

        96.69 

        1 of 1 

        CDC42 

        Takenouchi-Kosaki Syndrome,
         Macrothrombocytopenia-
        Lymphedema-Developmental
        Delay-Facial Dysmorphism-
        Camptodactyly Syndrome
         

        AD 

        99.97 

        10 of 10 

        EPHB4 

        Nonimmune Hydrops
        Fetalis And/Or Atrial Septal
        Defect
         

        AD 

        100 

        65 of 65 

        FGD1 

        Aarskog-Scott
         Syndrome
         

        X,XR,G 

        98.95 

        NA of NA 

        HRAS 

        Costello Syndrome, 
        Schimmelpenning-Feuerstein-
        Mims Syndrome, Linear
        Nevus Sebaceus Syndrome
         

        AD 

        100 

        34 of 34 

        KAT6B 

        Genitopatellar Syndrome,
         Ohdo Syndrome, 
        Blepharophimosis-Intellectual
        Disability Syndrome
         

        AD 

        99.97 

        80 of 80 

        KRAS 

        Aplasia
        Cutis Congenita With Epibulbar 
        Dermoids , Cardiofaciocutaneous 
        Syndrome, Noonan Syndrome, Ras-
        Associated Autoimmune 
        Lymphoproliferative Syndrome
         Type IV, Schimmelpenning
        -Feuerstein-Mims Syndrome,
         Cardiofaciocutaneous Syndrome,
         Encephalocraniocutaneous
         Lipomatosis, Toriello-Lacassie
        -Droste Syndrome
         

        AD 

        100 

        38 of 38 

        LZTR1 

        Noonan Syndrome 

        AD 

        99.99 

        136 of 136 

        MAP2K1 

        Cardiofaciocutaneous 
        Syndrome, Noonan Syndrome
         

        AD 

        100 

        31 of 31 

        MAP2K2 

        Cardiofaciocutaneous Syndrome,
        Neurofibromatosis-Noonan
        Syndrome
         

        AD 

        100 

        37 of 37 

        MAP3K8 

        Susceptibility To Lung
         Cancer
         

        AD 

        99.91 

        1 of 1 

        MRAS 

        Noonan Syndrome 

        AD 

        100 

        3 of 3 

        NF1 

        Neurofibromatosis-Noonan
        Syndrome,
        Neurofibromatosis Type I,
        Watson
        Syndrome, Deletion
         

        AD 

        97.97 

        3082 of 3166 

        NRAS 

        Neurocutaneous Melanosis,
        Noonan Syndrome,
        Ras-Associated Autoimmune
        Lymphoproliferative Syndrome
        Type IV, Schimmelpenning-
        Feuerstein-Mims Syndrome
         

        AD 

        100 

        15 of 15 

        PPP1CB 

        Noonan Syndrome-Like
        Disorder With Loose
        Anagen Hair
         

        AD 

        99.87 

        12 of 12 

        PTPN11 

        Leopard Syndrome, 
        Metachondromatosis, 
        Noonan Syndrome
         

        AD 

        100 

        150 of 151 

        RAF1 

        Cardiomyopathy Dilated
        Cardiomyopathy, Leopard
        Syndrome, Noonan
        Syndrome
         

        AD 

        100 

        64 of 64 

        RASA1 

        Capillary Malformation-
        Arteriovenous Malformation,
        Parkes Weber Syndrome
         

        AD 

        99.56 

        169 of 169 

        RASA2 

        Noonan Syndrome 

         

        99.82 

        5 of 5 

        RIT1 

        Noonan Syndrome 

        AD 

        99.85 

        27 of 27 

        RRAS 

        Noonan Syndrome 

         

        95.86 

        3 of 3 

        RRAS2 

        Noonan Syndrome 

        AD 

        99.8 

        6 of 6 

        SASH1 

        Pigment Dyscrasia,
        Onychodystrophy,
        And Keratoderma, 
        Dyschromatosis
         Universalis Hereditaria
         

        AD,AR 

        99.86 

        15 of 15 

        SHOC2 

        Noonan Syndrome-
        Like Disorder With 
        Loose Anagen Hair
         

        AD 

        99.98 

        8 of 8 

        SOS1 

        Hereditary Gingival
        Fibromatosis,
        Noonan Syndrome
         

        AD 

        100 

        103 of 104 

        SOS2 

        Noonan Syndrome 

        AD 

        99.48 

        6 of 7 

        SPRED1 

        Legius Syndrome 

        AD 

        100 

        84 of 84 

         * Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial 

        ** HGMD: Number of clinically relevant mutations according to HGMD 

        Methodology

        References

        See scientific referrals

        Romano, A. A., Allanson, J. E., Dahlgren, J., Gelb, B. D., Hall, B., Pierpont, M. E., Roberts, A. E., Robinson, W., Takemoto, C. M., & Noonan, J. A. (2010). Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics, 126(4), 746–759. https://doi.org/10.1542/peds.2009-3207 

        Turner, A. (2011). Noonan syndrome. Journal Of Paediatrics And Child Health, 50(10), E14-E20. doi: 10.1111/j.1440-1754.2010.01970.x 

        Cessans, C., Ehlinger, V., Arnaud, C., Yart, A., Capri, Y., & Barat, P. et al. (2016). Growth patterns of patients with Noonan syndrome: correlation with age and genotype. European Journal Of Endocrinology, 174(5), 641-650. doi: 10.1530/eje-15-0922 

        Turner A. M. (2014). Noonan syndrome. Journal of paediatrics and child health, 50(10), E14–E20. https://doi.org/10.1111/j.1440-1754.2010.01970.x 

        Allanson, J., Bohring, A., Dörr, H., Dufke, A., Gillessen-Kaesbach, G., & Horn, D. et al. (2010). The face of Noonan syndrome: Does phenotype predict genotype. American Journal Of Medical Genetics Part A, 152A(8), 1960-1966. doi: 10.1002/ajmg.a.33518 

        Liao, J., & Mehta, L. (2019). Molecular Genetics of Noonan Syndrome and RASopathies. Pediatric endocrinology reviews : PER, 16(Suppl 2), 435–446. https://doi.org/10.17458/per.vol16.2019.lm.molecularnoonan 

        Rauen K. A. (2013). The RASopathies. Annual review of genomics and human genetics, 14, 355–369. https://doi.org/10.1146/annurev-genom-091212-153523 

        Aoki, Y., Niihori, T., Inoue, S., & Matsubara, Y. (2016). Recent advances in RASopathies. Journal of human genetics, 61(1), 33–39. https://doi.org/10.1038/jhg.2015.114 

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        Fertilité

        Fertilité
        Éviter les maladies génétiques

        Test prénatal non-invasif

        Pour voir le certificat d'accréditation, l'annexe technique associée et la liste des tests accrédités, cliquez sur ce lien.

        Nos services

        Nos services
        Patients
        D'envoyer les échantillons
        Manuel d'utilisateur

        À propos d’Igenomix

        À propos d’Igenomix
        Igenomix dans le monde
        Quality
        Work with us

        SUIVRE IGENOMIX

          + 96 390 53 10
        Écrivez-nous
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        France

        [2021] © Igenomix Politique de confidentialité Politique de qualité Note juridique Politique de cookiesActualités et presse 

        Demander des informations


        • reCAPTCHA demo: Simple page

        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        • France
        • +34 96 390 53 10 Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        France
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.